Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Increases Price Target on Public Offering

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion today updated a planned offering of its common stock to raise as much as $33.9 million.

In an amended S-1 filing with the US Securities and Exchange Commission, the Austin, Texas-based diagnostics company said that it plans to offer up to 4 million shares of its stock at a maximum price of $7.36 per share.

Roth Capital Partners, the underwriter on the planned offering, also has the option to purchase 600,000 shares to cover overallotments, if any.

Today's filing increases the total Vermillion hopes to raise in the offering by doubling the number of shares it plans to offer while lowering the share price. Two weeks ago, Vermillion originally filed its prospectus with a planned offering of 2,098,539 shares at a maximum price of $8.22 per share, to raise up to $17.3 million.

The company did not say how much in net proceeds are expected from the offering, but said that the funds will be used to expand into international markets, support clinical trials for its peripheral artery disease test, "pursue opportunities to diversity our product and service lines and offerings," and general corporate purposes.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.